EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis.

Emmanuel Coronel, Irina M Cazacu, Atsushi Sakuraba, Adriana Alexandra Luzuriaga Chavez, Angad Uberoi, Yimin Geng, Yutaka Tomizawa, Adrian Saftoiu, Eun Ji Shin, Cullen M Taniguchi, Albert C Koong, Joseph M Herman, Manoop S Bhutani

Journal: Gastrointestinal endoscopy 2019;89(4):659-670.e18

PMID: 30445001

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND AND AIMS

Image-guided radiotherapy (IGRT) allows the delivery of radiation with high precision to a target lesion while minimizing toxicity to surrounding tissues. EUS provides excellent visualization of GI tumors and consequently is being used for fiducial placement with increased frequency. Our goal was to perform a systematic review and meta-analysis of studies evaluating the technical aspects, safety, and efficacy of EUS fiducial placement for IGRT in GI malignancies.

METHODS

A systematic literature search was carried out in the following databases: Medline, PubMed, Embase, Web of Science, and Cochrane Library, using Medical Subject Headings terms combined with text words. A random effects model was used to determine pooled proportions of technical success, migration, and adverse event rates. Heterogeneity was assessed using the I statistic. Publication bias was assessed visually using a funnel plot and by the Begg and Egger tests.

RESULTS

Nine full articles and 5 abstracts reporting on 1155 patients, 49% from a single study by Dhadham et al, were included in the meta-analysis. The pooled rate of technical success was 98% (95% confidence interval [CI], 96-99). Moderate heterogeneity (I = 34.18) was present, which appeared to be due to variable sample sizes. Publication bias was present, suggesting that studies with less-substantial outcomes may have not been reported (Begg test, P = .87; Egger test, P < .01). Pooled rates for fiducial migration and adverse events were 3% (95% CI, 1.0-8.0) and 4% (95% CI, 3-7), respectively.

CONCLUSIONS

Our meta-analysis showed that EUS-guided insertion of gold fiducials for IGRT is technically feasible and safe. Further controlled studies assessing its long-term effectiveness in GI malignancies are needed.

Address: Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Gastroenterology, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Craiova, Romania.; Department of Gastroenterology, University of Chicago, Chicago, Illinois, USA.; MD Anderson Cancer Center Library, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Gastroenterology, University of Washington, Seattle, Washington, USA.; Department of Gastroenterology, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Craiova, Romania.; Division of Gastroenterology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

DOI: 10.1016/j.gie.2018.10.047

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Endosonography, Fiducial Markers, Gastrointestinal Neoplasms, Humans, Prosthesis Implantation, Radiotherapy, Image-Guided, Ultrasonography, Interventional